Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals announced that the European Commission has authorized marketing of IMCIVREE® (setmelanotide) for treating obesity and controlling hunger in adults and children 4 years and older with acquired hypothalamic obesity (HO) due to hypothalamic injury or impairment. This follows FDA approval in the US and is based on Phase 3 TRANSCE…